GABA receptor

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

Retrieved on:

Tuesday, June 8, 2021

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.

Key Points:

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.
While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on 3 containing receptors.
Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.

Retrieved on:

Thursday, March 11, 2021

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.

Key Points:

Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors.
In September 2020, the U.S. Food and Drug Administration (FDA) released a Drug Safety Communication (DSC) detailing the risks associated with use of benzodiazepines.
PH10 is a new generation antidepressant with a mechanism of action that is designed to be fundamentally different from all current FDA-approved antidepressants.
PH10 is a Phase 2 investigational pherine nasal spray designed to have rapid-onset effects and therapeutic potential in several neuropsychiatric indications involving depression.

Retrieved on:

Wednesday, March 6, 2019

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).

Key Points:

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).
However, because drugs like BZDs can mimic these chemicals, they are used to stimulate the activity of GABAR in the lab.
The prolongation of reflex loss seen in mice given diazepam was thus linked directly to GABAR and inflammation in the brain.
GABA attaches to its receptor (GABAR) on the brain cells and induces inhibitory effects i.e., it decreases brain activity by calming it down.

Retrieved on:

Wednesday, March 6, 2019

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).

Key Points:

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).
However, because drugs like BZDs can mimic these chemicals, they are used to stimulate the activity of GABAR in the lab.
The prolongation of reflex loss seen in mice given diazepam was thus linked directly to GABAR and inflammation in the brain.
GABA attaches to its receptor (GABAR) on the brain cells and induces inhibitory effects i.e., it decreases brain activity by calming it down.

Retrieved on:

Tuesday, February 19, 2019

The "GABA Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points:

The "GABA Receptor Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
GABA Receptor Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across GABA Receptor Antagonist development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Offers detailed therapeutic product profiles of GABA Receptor Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Retrieved on:

Tuesday, December 4, 2018

Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.

Key Points:

Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.
The main inhibitory receptor in the mammalian brain, GABA-A-receptors (GABAARs), are activated by the neurotransmitter GABA, which is released from neurons.
Thus, modulation of the signaling pathways that regulate s-GABARs activity may provide new and safer treatments for epilepsy.
Dr. Sylantyev said that "GABA-independent modulation of spontaneously opening GABA-receptors is a perspective direction for the search for new anti-epileptic drugs free from common side effects."

Retrieved on:

Tuesday, October 23, 2018

The results are presented this week at the international conference Immunology of Diabetes Society Congress 2018 in London.

Key Points:

The results are presented this week at the international conference Immunology of Diabetes Society Congress 2018 in London.
"The results are encouraging and strengthen previously published immunological and clinical findings," says Rosaura Casas, Associate Professor of experimental pediatric immunology at Linkping University.
"The most interesting finding is that intralymphatic treatment with GAD can create a specific and lasting shift in the body's immune response."
Exclusive licenses for GABA and positive allosteric modulators of GABA receptors for the treatment of diabetes and inflammatory diseases constitutes alongside with the diabetes vaccine Diamyd and Remygen key assets.